Merck secures a positive CHMP opinion to expand Winrevair's PAH use, potentially broadening treatment to adult patients across WHO FC II-IV.
Merck leans on a fast-growing pipeline and new product launches to aid long-term growth as Keytruda's 2028 LOE nears.
Merck (MRK) closed at $99.01 in the latest trading session, marking a +1.42% move from the prior day.
Merck holds bullish momentum as pipeline advances and major deals offset vaccine weakness and Keytruda risks.
The U.S. Food and Drug Administration granted conditional approval for a Merck Animal Health pour-on treatment for the prevention and treatment of New World Screwworm, with farmers able to receive doses by December 20. U.S. cattle herds are at historic lows, pressuring beef prices, with the parasite from Mexico among multiple reasons for the decline in ranchers' livestock.
MRK banks on Capvaxive, Winrevair and other new launches to counter Keytruda's looming 2028 LOE and record long-term growth.
Merck & Co., Inc. (MRK) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
One of Merck's key assets has just scored a significant phase 2 win, boosting investor confidence. This adds to other recent developments that could help the company overcome its challenges.
Merck (MRK) demonstrates excellence across the board through its resilient revenue mix, expanding profitability, and stellar capital allocation. MRK's innovation, highlighted by Keytruda's dominance and diversified revenue streams, supports strong profitability and mitigates concentration risk. MRK's proven investment track record and consistent dividend growth further reinforce its appeal as a long-term investment opportunity.
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.